摘要
目的探讨参莲胶囊联合多西他赛注射液和卡铂注射液治疗晚期胃癌的临床疗效。方法选取2012年4月—2017年1月在启东市人民医院治疗的晚期胃癌患者62例,根据用药的差别分为对照组(31例)和治疗组(31例)。对照组静脉滴注多西他赛注射液,75 mg/m2,滴注1 h,3周1个疗程,每个疗程第1天滴注,同时静脉滴注卡铂注射液,300~400 mg/m2,给药时间同多西他赛注射液。治疗组在对照组的基础上口服参莲胶囊,3 g/次,3次/d。两组均经过12周治疗。观察两组患者临床疗效,同时比较治疗前后两组患者肿瘤标志物水平、血清学指标和QLQ-C30评分。结果治疗后,对照组客观反应率和临床获益率分别为25.81%和54.84%,均分别显著低于治疗组的51.61%和70.97%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清癌胚抗原(CEA)、糖抗原199(CA-199)水平均显著降低(P<0.05),且治疗组CEA和CA-199水平明显低于对照组(P<0.05)。治疗后,两组患者血清S100钙结合蛋白A4(S100A4)、胰岛素样生长因子1(IGF-1)、基质金属蛋白酶9(MMP-9)水平均显著降低(P<0.05),白细胞介素-2(IL-2)和干扰素-γ(IFN-γ)水平均显著增加(P<0.05),且治疗组这些血清学指标改善后水平明显优于对照组(P<0.05)。治疗后,两组患者QLQ-C30评分均显著升高意义(P<0.05),且治疗组QLQ-C30各评分项目升高程度比对照组更明显(P<0.05)。结论参莲胶囊联合多西他赛注射液和卡铂注射液治疗晚期胃癌可有效降低机体肿瘤标志物水平,提高机体免疫力,抑制血管新生因子和细胞侵袭分子水平,提高患者生活质量。
Objective To investigate the clinical efficacy of Shenlian Capsules combined with DP therapeutic regimen in treatment of advanced gastric cancer. Methods Patients（62 cases） with advanced gastric cancer in Qidong People＇s Hospital from April 2012 to January 2017 were divided into control（31 cases） and treatment（31 cases） groups based on different treatments. Patients in the control group were iv administered with Docetaxel Injection at the first day of each course of treatment, 75 mg/m2, dripped for 1 h, 3 weeks was a course of treatment, and they were iv administered with Carboplatin Injection, 300 — 400 mg/m2, the administration time was same with Docetaxel Injection. Patients in the treatment group were po administered with Shenlian Capsules on the basis of the control group, 3 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and the tumor markers, the serological indexes and the QLQ-C30 scores in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate were 25.81% and 54.84%, which were significantly lower than 51.61% and 70.97% in the treatment group, respectively, and there were differences between two groups（P〈 0.05）. After treatment, the CEA and CA-199 levels in two groups were significantly decreased（P〈 0.05）, and the CEA and CA-199 levels in the treatment group after treatment were significantly lower than those in the control group（P〈 0.05）. After treatment, the serum S100 A4, IGF-1 and MMP-9 levels in two groups were significantly decreased（P〈 0.05）, the IL-2 and IFN-γ levels were significantly increased（P〈 0.05）, and the serological indexes in the treatment group after treatment were significantly better than those in the control group（P〈 0.05）. After treatment, the QLQ-C30 scores in two groups were significantly increased（P〈 0.05）, and the scores in the treatment group after treatment wer
作者
唐小慧
王娟娟
唐鸣
陈坤燕
TANG Xiao-hui;WANG Juan-juan;TANG Ming;CHEN Kun-yan(Department of Ontology,Qidong People＇s Hospital,Qidong 226200,China)
出处
《现代药物与临床》
CAS
2018年第8期2055-2059,共5页
Drugs & Clinic
